These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8357303)

  • 41. Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2 -diphenylethanes.
    Hartmann RW; Kranzfelder G; von Angerer E; Schönenberger H
    J Med Chem; 1980 Aug; 23(8):841-8. PubMed ID: 7401112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platinum and palladium complexes containing ethylenediamine derivatives as carrier ligands and their antitumor activity.
    Lee K; Tashiro T; Noji M
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):702-3. PubMed ID: 8004720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of N,N'-diethyl-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines on the 7,12-dimethylbenz[a]anthracene-induced mammary carcinoma of the rat.
    von Angerer E
    J Med Chem; 1982 Nov; 25(11):1374-7. PubMed ID: 6815325
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of alkyl-chain fluorination on the action of mammary tumor inhibiting 2,3-bis(hydroxyphenyl)butanes and 2,3-bis(hydroxyphenyl)but-2-enes.
    Hartmann RW; Heindl A; Schneider MR; Schönenberger H
    J Med Chem; 1986 Mar; 29(3):322-8. PubMed ID: 3005573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis, characterization and in vitro antitumour activity of a series of novel platinum(II) complexes bearing Schiff base ligands.
    Proetto M; Liu W; Hagenbach A; Abram U; Gust R
    Eur J Med Chem; 2012 Jul; 53():168-75. PubMed ID: 22534185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combinations of interferon with platinum complexes: synergistic and antagonistic effects on growth inhibition of MCF-7 and MDA-MB231 breast cancer cells.
    Otto AM
    J Cancer Res Clin Oncol; 1994; 120(5):286-92. PubMed ID: 7510292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3-Alkyl-2-phenylbenzo[b]thiophenes: nonsteroidal estrogen antagonists with mammary tumor inhibiting activity.
    von Angerer E; Erber S
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):557-62. PubMed ID: 1562527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Synthetic estrogens--new pharmacological actions and mechanisms].
    Kosano H; Nishigori H
    Nihon Rinsho; 1994 Mar; 52(3):587-92. PubMed ID: 8164354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [1,2-Bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloro-platinum(II): an endocrine-active platinum complex with a specific prostatic tumor-inhibiting activity.
    Schneider MR; Schiller CD; Humm A; Spruss T; Schönenberger H; Amselgruber W; Sinowatz F
    Prostate; 1989; 15(2):135-48. PubMed ID: 2798231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inversion of the cis geometry requirement for cytotoxicity in structurally novel platinum(II) complexes containing the bidentate N,O-donor pyridin-2-yl-acetate.
    Bierbach U; Sabat M; Farrell N
    Inorg Chem; 2000 May; 39(9):1882-90. PubMed ID: 11428108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 2-Alkyl-substituted 1,1-bis(4-acetoxyphenyl)-2-phenylethenes. Estrogen receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activity.
    Schneider MR
    J Med Chem; 1986 Aug; 29(8):1494-8. PubMed ID: 3735317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens.
    Labaree DC; Zhang JX; Harris HA; O'Connor C; Reynolds TY; Hochberg RB
    J Med Chem; 2003 May; 46(10):1886-904. PubMed ID: 12723952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.
    Jennerwein M; Gust R; Müller R; Schönenberger H; Engel J; Berger MR; Schmähl D; Seeber S; Osieka R; Atassi G
    Arch Pharm (Weinheim); 1989 Feb; 322(2):67-73. PubMed ID: 2730292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding.
    Kapp T; Dullin A; Gust R
    J Med Chem; 2006 Feb; 49(3):1182-90. PubMed ID: 16451082
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platinum(II) complexes containing long-chain hydrophobic N-alkyl-diamine ligands: synthesis, characterization, molecular modeling, and cytotoxic activity.
    Tavares TT; Teixeira GF; Lopes CM; Novato WT; Silva H; Lopes MT; De Almeida MV; Grazul RM; Dos Santos HF; Fontes AP
    J Inorg Biochem; 2012 Oct; 115():13-9. PubMed ID: 22922288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
    Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
    J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enantiomerically pure [1, 2-diamino-1-(4-fluorophenyl)butane]platinum(II) complexes: synthesis and antitumor activity against MCF-7 and MDA-MB 231 breast cancer and LnCaP/FGC prostate cancer cell lines.
    Dullin A; Dufrasne F; Gelbcke M; Gust R
    Arch Pharm (Weinheim); 2004 Dec; 337(12):654-67. PubMed ID: 15597399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Asymmetrically substituted ethylenediamine platinum(II) complexes as antitumor agents: synthesis and structure-activity relationships.
    Mailliet P; Segal-Bendirdjian E; Kozelka J; Barreau M; Baudoin B; Bissery MC; Gontier S; Laoui A; Lavelle F; Le Pecq JB
    Anticancer Drug Des; 1995 Jan; 10(1):51-73. PubMed ID: 7695813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platinum complexes of oxopurines: cis-bis(theophyllinato-N7)bis(triphenylphosphine)platinum(II) and cis-chloro(theobrominato-N1)bis(triphenylphosphine)platinum(II) ethanol hemisolvate.
    Dubler E; Schmalle HW; Arod F; Schneider A
    Acta Crystallogr C; 2002 Feb; 58(Pt 2):m111-5. PubMed ID: 11828097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.